PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Family Medicine, Faculty of Medicine, Baskent University, Baglica Kampusu, Etimesgut, Ankara, Turkey. eoksuz@baskent.edu.tr.\', \'Department of Health Care Management, Faculty of Health Sciences, Baskent University, Ankara, Turkey.\', \'Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.\', \'Cerrahpasa Medical School Hospital, Istanbul University, Istanbul, Turkey.\', \'Istanbul University Hospitals, Istanbul, Turkey.\', \'HEOR, Global Value and Access Europe, Gilead Sciences, Foster City, CA, USA.\', \'Gilead Sciences Turkey, Istanbul, Turkey.\', \'Department of Infectious Disease, Cerrahpasa Medical School, Istanbul University, Istanbul, Turkey.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1007/s12325-021-01874-9
?:hasPublicationType
?:journal
  • Advances in therapy
is ?:pmid of
?:pmid
?:pmid
  • 34379304
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.075
?:rankingScore_hIndex
  • 51
is ?:relation_isRelatedTo_publication of
?:title
  • Cost-Effectiveness Analysis of Remdesivir Treatment in COVID-19 Patients Requiring Low-Flow Oxygen Therapy: Payer Perspective in Turkey.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34379304>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34379304>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all